AU2005214349B2 - Substituted azole derivatives, compositions, and methods of use - Google Patents

Substituted azole derivatives, compositions, and methods of use Download PDF

Info

Publication number
AU2005214349B2
AU2005214349B2 AU2005214349A AU2005214349A AU2005214349B2 AU 2005214349 B2 AU2005214349 B2 AU 2005214349B2 AU 2005214349 A AU2005214349 A AU 2005214349A AU 2005214349 A AU2005214349 A AU 2005214349A AU 2005214349 B2 AU2005214349 B2 AU 2005214349B2
Authority
AU
Australia
Prior art keywords
phenyl
dichloro
imidazol
biphenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005214349A
Other languages
English (en)
Other versions
AU2005214349A1 (en
Inventor
Robert C. Andrews
Murty N. Arimilli
Adnan M.M. Mjalli
Dharma R. Polisetti
James C. Quada Jr.
Govindan Subramanian
Rongyuan Xie
Ravindra R. Yarragunta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Publication of AU2005214349A1 publication Critical patent/AU2005214349A1/en
Assigned to TRANSTECH PHARMA, INC. reassignment TRANSTECH PHARMA, INC. Request for Assignment Assignors: TRANSTECH PHARMA INC.
Application granted granted Critical
Publication of AU2005214349B2 publication Critical patent/AU2005214349B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005214349A 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use Ceased AU2005214349B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54397104P 2004-02-12 2004-02-12
US60/543,971 2004-02-12
PCT/US2005/004590 WO2005080346A1 (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use

Publications (2)

Publication Number Publication Date
AU2005214349A1 AU2005214349A1 (en) 2005-09-01
AU2005214349B2 true AU2005214349B2 (en) 2011-11-03

Family

ID=34885991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005214349A Ceased AU2005214349B2 (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions, and methods of use

Country Status (10)

Country Link
US (2) US20050187277A1 (https=)
EP (1) EP1730118A1 (https=)
JP (1) JP4898458B2 (https=)
CN (1) CN1922151A (https=)
AU (1) AU2005214349B2 (https=)
CA (1) CA2551909C (https=)
IL (1) IL176571A0 (https=)
NZ (1) NZ548208A (https=)
WO (1) WO2005080346A1 (https=)
ZA (1) ZA200605526B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527920A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
EP1723120A4 (en) * 2004-03-08 2007-09-26 Wyeth Corp MODULATORS OF THE ION CHANNEL FUNCTION
RU2361872C2 (ru) * 2004-05-26 2009-07-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циннамидное соединение
BRPI0510929A (pt) * 2004-06-18 2007-07-17 Chiron Corp derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer
DE602005019602D1 (de) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
JP2008530197A (ja) * 2005-02-18 2008-08-07 イノディア インク. 4−ヒドロキシイソロイシンの類似体及びその使用
EP1874287A2 (en) * 2005-03-22 2008-01-09 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
KR20080069221A (ko) * 2005-11-24 2008-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 모르폴린 타입의 신나미드 화합물
NZ569329A (en) * 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR059955A1 (es) * 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US20100048545A1 (en) * 2006-03-22 2010-02-25 Innodia Inc. Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
US7737141B2 (en) * 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US8106070B2 (en) * 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2666310C (en) * 2006-10-20 2012-07-31 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) * 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CN101605788A (zh) * 2006-12-11 2009-12-16 默克公司 用作铃蟾肽受体亚型-3调节剂的取代的二氮杂磺酰胺类化合物
WO2008086122A2 (en) * 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
CL2008000582A1 (es) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
BRPI0815773A2 (pt) 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd composto, e, medicamento.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2009096349A1 (ja) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. 結晶性のシンナミド化合物またはその塩
US8394969B2 (en) * 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010041614A1 (en) * 2008-10-06 2010-04-15 Shikoku Chemicals Corporation 2-benzyl-4-(2,4-dichlorophenyl)-5-methylimidazole compound
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
CA2759083A1 (en) 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 2−(2,4−ジクロロベンジル)−4−アリール−5−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 4−(2,4−ジクロロフェニル)−5−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 4−(4−ビフェニリル)−2−(2,4−ジクロロベンジル)イミダゾールおよび表面処理液
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 2−(ブロモベンジル)−4−(ブロモフェニル)−5−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 4−(ジクロロフェニル)−2−(4−フルオロベンジル)−5−メチルイミダゾール化合物
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
US8685966B2 (en) 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
WO2014123203A1 (ja) * 2013-02-06 2014-08-14 京都薬品工業株式会社 糖尿病治療薬
EP3013796B9 (en) * 2013-06-27 2020-07-01 LG Chem, Ltd. Biaryl derivatives as gpr120 agonists
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN109825849B (zh) * 2019-01-25 2021-02-19 华南理工大学 一种三氟甲基乙烯基类化合物的电化学制备方法
KR20230084530A (ko) * 2020-10-09 2023-06-13 브리스톨-마이어스 스큅 컴퍼니 아미노이미다졸 fpr2 효능제
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008982A1 (fr) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Derives oxazole et thiazole
WO2000071120A1 (en) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Antibacterial compounds
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
EP1227084A1 (en) * 1999-10-28 2002-07-31 Microcide Pharmaceuticals, Inc. Drug discharge pump inhibitors
EP1253142A1 (en) * 2000-01-24 2002-10-30 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
WO2003048140A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2004210711A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
CA2009925C (en) * 1989-02-14 2002-10-01 Koichi Kondo Method for enhancement of chemiluminescence
ATE205202T1 (de) * 1992-03-13 2001-09-15 Merck Sharp & Dohme Imidazol-, triazol- und tetrazolderivate
ATE202571T1 (de) * 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US6238902B1 (en) * 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
AU9253798A (en) * 1997-09-23 1999-04-12 Novo Nordisk A/S Modules of protein tyrosine phosphatases (ptpases)
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
CA2331056A1 (en) * 1998-05-12 1999-12-02 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
EP1119614B1 (en) * 1998-07-24 2009-12-09 Merck Frosst Canada Ltd. Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
US6534056B1 (en) * 1998-12-11 2003-03-18 Mcgill University Therapeutic and diagnostic uses of protein tyrosine phosphatase TC-PTP
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
CA2372116A1 (en) * 1999-05-14 2000-11-23 Claude Dufresne Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
WO2001016097A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
JP2003518128A (ja) * 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ1b(ptp−1b)のインヒビターとなる芳香族ホスホネート
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6486141B2 (en) * 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
CA2393363A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6486142B2 (en) * 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
JP2003520049A (ja) * 2000-01-18 2003-07-02 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒトタンパク質であるチロシンホスファターゼのポリヌクレオチド、ポリペプチド、および抗体
US20020009762A1 (en) * 2000-02-14 2002-01-24 Flint Andrew J. Assay for protein tyrosine phosphatases
US6498151B2 (en) * 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
EP1284260A4 (en) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSIN PHOSPHATASE INHIBITORS
DE60135752D1 (en) * 2000-07-06 2008-10-23 Array Biopharma Inc Tyrosinderivate als phosphatase inhibitoren
US20020099073A1 (en) * 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US6613903B2 (en) * 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6972340B2 (en) * 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US20020035137A1 (en) * 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
GB0022079D0 (en) * 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
US20030108883A1 (en) * 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) * 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) * 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換5−員窒素含有複素環
WO2003032982A1 (en) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
JP2005508968A (ja) * 2001-10-19 2005-04-07 トランス テック ファーマ,インコーポレイテッド PTP阻害剤としてのβ−カルボリン誘導体
US6642381B2 (en) * 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) * 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) * 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
KR100868587B1 (ko) * 2002-04-03 2008-11-12 노파르티스 아게 Ptpase 1b 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체
AU2003216579A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US20040009956A1 (en) * 2002-04-29 2004-01-15 Dehua Pei Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
US7399586B2 (en) * 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
DE60304718T2 (de) * 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US6849761B2 (en) * 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
EP1594497B1 (en) * 2002-12-30 2009-05-27 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7135493B2 (en) * 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
NZ569329A (en) * 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008982A1 (fr) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Derives oxazole et thiazole
WO2000071120A1 (en) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Antibacterial compounds
EP1227084A1 (en) * 1999-10-28 2002-07-31 Microcide Pharmaceuticals, Inc. Drug discharge pump inhibitors
EP1253142A1 (en) * 2000-01-24 2002-10-30 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
WO2003048140A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2003093263A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2004210711A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAS Registry number 101341-14-4 *
CAS Registry number 143150-90-7 *
CAS Registry number 143182-51-8 *
CAS Registry number 96271-51-1 *
CAS Registry number 96772-99-5 *
CAS Registry number 96975-63-2 *
CAS Registry number 98016-87-6 *
Cocco, M. T. et al (1992) Il. Farm. 47:229-238 *
Laufer, S. A. et al (2002) J. Med. Chem. 45:4695-4705 *
Lipshutz, B. H. and Hungate, R. W. (1981) J. Org. Chem. 46:1410-1413 *
Meanwell, N. A. et al (1992) J. Med. Chem. 35:3483-3497 *

Also Published As

Publication number Publication date
US20050187277A1 (en) 2005-08-25
IL176571A0 (en) 2006-10-31
NZ548208A (en) 2010-09-30
US20110092553A1 (en) 2011-04-21
JP4898458B2 (ja) 2012-03-14
CA2551909C (en) 2011-10-11
CN1922151A (zh) 2007-02-28
AU2005214349A1 (en) 2005-09-01
EP1730118A1 (en) 2006-12-13
CA2551909A1 (en) 2005-09-01
ZA200605526B (en) 2007-11-28
JP2007523903A (ja) 2007-08-23
WO2005080346A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
AU2005214349B2 (en) Substituted azole derivatives, compositions, and methods of use
AU2004210711B2 (en) Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) Substituted azole derivatives as therapeutic agents
FI108434B (fi) Menetelmõ farmakologisesti vaikuttavien bentsimidatsolijohdannaisten valmistamiseksi
US7459472B2 (en) Aryl and heteroaryl compounds, compositions, and methods of use
AU2007211319B9 (en) Substituted imidazole derivatives and their use as PTPase inhibitors
US20040014778A1 (en) Heteroaryl - fused nitrogen heterocycles as therapeutic agents
US20060276518A1 (en) Aryl and heteroaryl compounds and methods to modulate coagulation
CA2525628C (en) New benzimidazole derivatives
US7115645B2 (en) 1,2 diarylbenzimidazoles and their pharmaceutical use
HRP20050816A2 (hr) Biaril supstituirani triazoli kao blokatori natrijevih kanala
HRP940346A2 (en) Imidazole 5-position substituted angiotensin ii antagonists
US6875765B2 (en) Arylsulfonamide ethers, and methods of use thereof
US7582673B2 (en) Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP2190811B1 (en) Renin inhibitors
KR20230116511A (ko) 벤즈옥사지논 유도체 및 그를 포함하는 약제학적 조성물
KR20230132191A (ko) Grk5 억제용 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 grk5 활성 관련 질환의 예방 또는 치료용 약학 조성물
US20210309616A1 (en) Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors
HUP0002054A2 (hu) N-4-(nitro-metil-szulfonil)-fenil-alkánamid és -benzolszulfonamid-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
JP2002255799A (ja) シクロブテン誘導体を含有する医薬組成物

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: TRANSTECH PHARMA, INC.

Free format text: FORMER NAME: TRANSTECH PHARMA INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired